"Dr. Zeeshan has expertise in performing an array of procedures, including open heart surgery, including heart and lung transplantation, aortic surgery, minimally invasive heart valve surgery, mitral valve procedures, aortic valve surgery and bloodless cardiac surgery. After completing medical school, Dr. Zeeshan trained in general surgery at the University of Pennsylvania and the University of Maryland. Then, Dr. Zeeshan completed a fellowship in cardiothoracic surgery at Yale University. He received specialized training in aortic surgery, including endovascular techniques, heart and lung transplantation and mechanical circulatory support surgery at Cleveland Clinic Ohio."

During the past decade, Florida Hospital Transplant Institute conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 4 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Florida Hospital Transplant Institute" #1 sponsor was "Bristol-Myers Squibb" with 4 trials, followed by "American Regent, Inc." with 1 trials sponsored, "Biotest Pharmaceuticals Corporation" with 1 trials sponsored, "Celgene" with 1 trials sponsored and "Conatus Pharmaceuticals Inc." with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Florida Hospital Transplant Institute" #1 collaborator was "Cardioxyl Pharmaceuticals, Inc" with 1 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator, "Genzyme, a Sanofi Company" with 1 trials as a collaborator and "Novartis" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Florida Hospital Transplant Institute" are "Heart Failure" (2 trials), "Hepatitis C" (2 trials), "Hepatocellular Carcinoma" (2 trials), "Acute Antibody-Mediated Rejection (AMR)" (1 trials) and "Decompensated Cirrhosis" (1 trials). Many other conditions were trialed in "Florida Hospital Transplant Institute" in a lesser frequency.

Most popular intervention types in "Florida Hospital Transplant Institute" are "Drug" (11 trials), "Biological" (2 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Ribavirin" (2 trials), "Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)" (1 trials), "BMS-650032" (1 trials) and "Cinryze®" (1 trials). Other intervention names were less common.

The vast majority of trials in "Florida Hospital Transplant Institute" are 13 trials for "All" genders.

Currently, there are NaN active trials in "Florida Hospital Transplant Institute". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Florida Hospital Transplant Institute, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Florida Hospital Transplant Institute, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".